Skip to content

Study of Kidney Circulating Cell-free DNA in Patients With Acute Kidney Failure

Study of the Quantitative Evolution of Circulating Cell-free DNA of Renal Origin in Patients With Acute Renal Failure

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05399420
Acronym
ADNIRA
Enrollment
90
Registered
2022-06-01
Start date
2022-09-10
Completion date
2023-01-10
Last updated
2022-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, Acute

Brief summary

The amount of total circulating DNA has been shown to increase in patients with acute renal failure. Nevertheless, it is currently not currently possible to prove the renal origin of this circulating DNA. Recently, in healthy subjects, teams have shown that it is possible to identify its tissue origin of circulating DNA. CGenetix is a MedTech company which develops on an identical principle an in vitro diagnostic test capable of identifying and quantifying renal degradation during an acute trauma. The objective of this study is to evaluate the sensitivity of the proposed technology to detect circulating DNA of renal origin released into the general circulation in patients with acute organic and functional renal failure. Patients with functional or organic kidney deficiency will be included and the kidney biomarkers develop by CGenetix will be compared between these 2 groups of patients.

Detailed description

When the patient arrives, a first stage of checking the inclusion/non-inclusion criteria will be respected. Patients who do not meet the eligibility criteria will not be sampled (pre-screening stage). Patients meeting the eligibility criteria will be informed of the study by the investigator and a written information note will be given to them. If they do not object to their participation, an additional tube of blood for research purposes will be taken during a blood sample taken as soon as they are admitted as part of their usual treatment. They will also follow the standard care protocol according to the clinical recommendations of their attending physician. The objective of early sampling is to sensitize the test by assaying the marker as soon as possible after renal injury. In the event of a posteriori differential diagnosis (obstructive ARF or IRC), the patient will be excluded from the final analysis. Patients passing the pre-screening and screening stages positively will be included in the final analysis. 90 patients should be included and divided into 2 groups: * 65 patients with non-biopsied organic acute kidney injury of which 20 patients with biopsied organic acute kidney injury (test group) * 25 patients with functional acute kidney failure (control group).

Interventions

DIAGNOSTIC_TESTBlood sampling

One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes

Sponsors

Centre Hospitalier Sud Francilien
CollaboratorOTHER
CGenetix
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years old * Admitted for suspicion of acute renal injury (organic) and/or with an indication for renal biopsy (PBR) * Patients hospitalized with functional acute renal failure (negative control and inclusion limited to n = 30 maximum)

Exclusion criteria

* Patients \< 18 years old * Patients with cognitive and mental disorders making them unable to express their non-objection to participation in the study * Patients with obstructive renal failure * Patients with chronic renal failure * Patients who expressed their refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Quantification of circulating cell-free DNA of renal origin at baseline (at patient hospital admission in nephrology department)Patient hospitalization timeHigher amount of circulating cell-free DNA of renal origin at the time of diagnosis of acute renal failure in patients with organ-type acute renal failure

Secondary

MeasureTime frameDescription
Comparison of circulating-cell-free DNA of renal origin amounts and kidney biopsy results at baseline (at patient hospital admission in nephrology department)Patient hospitalization timeHigher amount of circulating cell-free DNA of renal origin for patient with confirmed kidney lesions observed by histological analysis (kidney puncture)

Contacts

Primary ContactGeoffroy Poulet, PhD
geoffroy.poulet@cgenetix.com+33667772394
Backup ContactPierre Housset, MD
pierre.housset@chsf.fr+33161695186

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026